Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
Coastline Trust Co Buys 10,492 Shares of AbbVie Inc. $ABBV
05:28am, Friday, 20'th Mar 2026
Coastline Trust Co boosted its stake in AbbVie Inc. (NYSE: ABBV) by 27.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
The Smartest Dividend Stocks to Buy With $2,000 Right Now
04:44am, Friday, 20'th Mar 2026
AbbVie is a Dividend King poised to deliver solid growth. Chevron is well-positioned to capitalize on the new opportunities in Venezuela.
Farmers National Bank Increases Stake in AbbVie Inc. $ABBV
04:36am, Friday, 20'th Mar 2026
Farmers National Bank grew its holdings in AbbVie Inc. (NYSE: ABBV) by 66.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
06:46pm, Thursday, 19'th Mar 2026
AbbVie (ABBV) reached $206.23 at the closing of the latest trading day, reflecting a -1.01% change compared to its last close.
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
09:41am, Thursday, 19'th Mar 2026
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
Buy Or Fear AbbVie Stock At $210?
09:26am, Thursday, 19'th Mar 2026
AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson's Icotyde, the first oral IL-23 inhibitor on the market. This
Centaurus Financial Inc. Has $3.08 Million Holdings in AbbVie Inc. $ABBV
04:46am, Thursday, 19'th Mar 2026
Centaurus Financial Inc. increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 56.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange C
243,718 Shares in AbbVie Inc. $ABBV Bought by CIBC Bancorp USA Inc.
04:46am, Thursday, 19'th Mar 2026
CIBC Bancorp USA Inc. bought a new position in shares of AbbVie Inc. (NYSE: ABBV) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor boug
Allworth Financial LP Acquires 30,124 Shares of AbbVie Inc. $ABBV
03:58am, Thursday, 19'th Mar 2026
Allworth Financial LP grew its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 14.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 243,834 s
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results Comprehensive data-based educational solutions to be pre
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
What's Going On With AbbVie Stock Today?
12:26pm, Wednesday, 18'th Mar 2026
Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis.
Advisory Services Network LLC Trims Holdings in AbbVie Inc. $ABBV
03:25am, Wednesday, 18'th Mar 2026
Advisory Services Network LLC lessened its holdings in AbbVie Inc. (NYSE: ABBV) by 8.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exc
Big drugmakers must face US overcharge claims on medications for low-income patients
02:32pm, Tuesday, 17'th Mar 2026
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharg
AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
12:45pm, Tuesday, 17'th Mar 2026
AbbVie ABBV stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day SMA
